Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Amortization of Deferred Charges (2018 - 2022)

Historic Amortization of Deferred Charges for Avadel Pharmaceuticals (AVDL) over the last 5 years, with Q4 2022 value amounting to $1.9 million.

  • Avadel Pharmaceuticals' Amortization of Deferred Charges rose 51254.02% to $1.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $6.1 million, marking a year-over-year increase of 38493.59%. This contributed to the annual value of $2.8 million for FY2023, which is 5380.04% down from last year.
  • According to the latest figures from Q4 2022, Avadel Pharmaceuticals' Amortization of Deferred Charges is $1.9 million, which was up 51254.02% from $1.9 million recorded in Q3 2022.
  • In the past 5 years, Avadel Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $1.9 million in Q3 2022 and a low of $311000.0 during Q4 2021
  • Over the past 5 years, Avadel Pharmaceuticals' median Amortization of Deferred Charges value was $1.5 million (recorded in 2019), while the average stood at $1.2 million.
  • In the last 5 years, Avadel Pharmaceuticals' Amortization of Deferred Charges tumbled by 8158.67% in 2021 and then soared by 51474.36% in 2022.
  • Over the past 5 years, Avadel Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $1.4 million in 2018, then rose by 10.01% to $1.6 million in 2019, then grew by 7.51% to $1.7 million in 2020, then tumbled by 81.59% to $311000.0 in 2021, then skyrocketed by 512.54% to $1.9 million in 2022.
  • Its Amortization of Deferred Charges was $1.9 million in Q4 2022, compared to $1.9 million in Q3 2022 and $1.9 million in Q2 2022.